Roivant Sciences Ltd. $ROIV Shares Bought by Amundi

Amundi lifted its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 18.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 398,729 shares of the company’s stock after acquiring an additional 61,214 shares during the quarter. Amundi owned 0.06% of Roivant Sciences worth $3,991,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Parallel Advisors LLC increased its stake in shares of Roivant Sciences by 80.5% during the first quarter. Parallel Advisors LLC now owns 2,485 shares of the company’s stock worth $25,000 after acquiring an additional 1,108 shares during the period. UMB Bank n.a. increased its stake in shares of Roivant Sciences by 112.7% during the first quarter. UMB Bank n.a. now owns 4,143 shares of the company’s stock worth $42,000 after acquiring an additional 2,195 shares during the period. Russell Investments Group Ltd. increased its stake in shares of Roivant Sciences by 94.8% during the first quarter. Russell Investments Group Ltd. now owns 4,588 shares of the company’s stock worth $46,000 after acquiring an additional 2,233 shares during the period. Fifth Third Bancorp increased its stake in shares of Roivant Sciences by 59.3% during the first quarter. Fifth Third Bancorp now owns 5,118 shares of the company’s stock worth $52,000 after acquiring an additional 1,905 shares during the period. Finally, GAMMA Investing LLC increased its stake in shares of Roivant Sciences by 83.0% during the first quarter. GAMMA Investing LLC now owns 6,493 shares of the company’s stock worth $66,000 after acquiring an additional 2,945 shares during the period. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 1,195,000 shares of the stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $12.50, for a total transaction of $14,937,500.00. Following the transaction, the insider owned 36,089,108 shares of the company’s stock, valued at $451,113,850. This trade represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Eric Venker sold 100,000 shares of the firm’s stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $11.72, for a total transaction of $1,172,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,653,585 shares in the company, valued at approximately $19,380,016.20. This represents a 5.70% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,218,022 shares of company stock worth $39,010,006 in the last three months. Insiders own 10.80% of the company’s stock.

Wall Street Analyst Weigh In

ROIV has been the topic of a number of recent analyst reports. Citigroup initiated coverage on shares of Roivant Sciences in a research note on Tuesday, September 2nd. They set a “buy” rating and a $16.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Wednesday, June 18th. Finally, The Goldman Sachs Group upgraded shares of Roivant Sciences to a “strong-buy” rating and set a $19.00 target price on the stock in a research report on Thursday, July 10th. Two analysts have rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Strong Buy” and a consensus target price of $17.67.

Roivant Sciences Price Performance

ROIV stock opened at $13.77 on Thursday. The company’s 50 day simple moving average is $11.73 and its 200-day simple moving average is $11.08. The firm has a market capitalization of $9.40 billion, a PE ratio of -19.67 and a beta of 1.15. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $13.82.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.